MedApp has signed an agreement with StethoMe, a start-up developer of a solution for remote detection of respiratory abnormalities. As part of the partnership, MedApp’s digital medicine application will support a wireless stethoscope. The new device will expand the range of tests offered by medical facilities using CarnaLife System and Digital Clinic solutions.
StethoMe is the first solution for remote detection of abnormalities in the respiratory system. It is based on artificial intelligence algorithms with medical device status, working with a wireless stethoscope and adedicated application. With unique technologies to ensure the test’s quality, it can be used by patients remotely. The solution is particularly useful for people with conditions such as asthma, chronic obstructive pulmonary disease, diabetes, pneumonia, bronchitis and other respiratory conditions.
“StethoMe is one of the most innovative solutions available in the medical market today. We look forward to working together with the StethoMe team to deploy it at our partner facilities and enhance our app and services. Already, CarnaLife System and the Digital Clinic offer a wide spectrum of measurements and their analysis in the areas of internal medicine, cardiology or diabetology. With a wireless stethoscope, physicians from facilities using our solutions will be able to check the respiratory status of patients without making appointments. All remotely,” summarizes Krzysztof Mędrala, CEO of MedApp.
Read more See similar articles:
MedApp is the laureate of the Special Award of PARP and NCBR
During the Gala of the 24th edition of the Polish Product of the Future competition, we received a special award from the Polish Agency for Enterprise Development and the National Center for Research and Development!
East Value Research Analyst Report – update
An independent analyst report prepared by analysts at East Value Research was released today.
MedApp with record FY 2021 results, doubling revenue and profits from previous year
MedApp reported PLN 12.7 million in net sales revenue cumulatively after four quarters of 2021, 111% higher than a year earlier. EBITDA increased by 139% to PLN 6.3 million, and net profit was twice higher year-on-year, reaching PLN 3.8 million. The company also boasts high profitability.